New depression drug shows promise in early trial
Symptom relief
Recruiting now
This study tests a single injection of apimostinel, a fast-acting antidepressant, in 150 adults with major depression. Half also receive digital cognitive training sessions to see if it extends the drug's effects. The trial is placebo-controlled and double-blind, meaning neither …
Phase: PHASE2 • Sponsor: Rebecca Price • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC